This article provides a detailed comparison of two leading digital PCR platforms, Qiagen's QIAcuity and Bio-Rad's QX200, tailored for researchers, scientists, and drug development professionals.
The analysis of circulating tumor DNA (ctDNA) via liquid biopsy is revolutionizing cancer research and drug development.
This article provides a comprehensive analysis of the Limit of Detection (LOD) for circulating tumor DNA (ctDNA) using digital PCR (dPCR), specifically targeting researchers and drug development professionals.
The detection of circulating tumor DNA (ctDNA) is transforming precision oncology, but its clinical utility is constrained by the challenge of identifying ultra-low frequency variants against a high background of...
This article provides a comprehensive guide for researchers and drug development professionals on integrating automated liquid handling (ALH) into digital PCR (dPCR) workflows.
The analysis of circulating tumor DNA (ctDNA) through liquid biopsy has transformed oncology, enabling non-invasive cancer monitoring, therapy response assessment, and minimal residual disease detection.
This article provides a comprehensive guide for researchers and drug development professionals seeking to enhance the precision of copy number quantification.
This article provides a critical analysis of how freeze-thaw cycles impact circulating tumor DNA (ctDNA) integrity, a paramount pre-analytical variable in liquid biopsy.
Digital PCR (dPCR) has emerged as a powerful tool for the detection of circulating tumor DNA (ctDNA), enabling non-invasive monitoring of treatment response, minimal residual disease (MRD), and resistance mutations...
This article provides a comprehensive guide for researchers and drug development professionals on minimizing false positive signals in digital PCR (dPCR) for circulating tumor DNA (ctDNA) analysis.